CurrentUnitedHealthcarePolicy N/A

Vafseo (vadadustat) prior authorization for dialysis-dependent CKD anemia

Defines UnitedHealthcare prior authorization and reauthorization requirements for Vafseo (vadadustat) for treatment of anemia in adults with chronic kidney disease who have been receiving dialysis for at least three months.

Policy Summary

PayerUnitedHealthcare

PolicyVafseo (vadadustat) prior authorization for dialysis-dependent CKD anemia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateDec 1, 2025

Next Review DateSep 1, 2025

Key ActionObtain prior authorization documenting diagnosis of anemia due to CKD and that the patient has been receiving dialysis for at least three months.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

adults on dialysistreated population

9/2024 & 9/2025P&T approval

package insertprimary reference

Coverage Criteria for Vafseo (vadadustat)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Initial Authorization

Covered when ALL of the following are met

Initial Authorization for Vafseo: Diagnosis of anemia due to chronic kidney disease (CKD)

Authorization issued for 12 months

Initial Authorization for Vafseo: Patient has been receiving dialysis for at least three months

Authorization issued for 12 months

Vafseo is not indicated for use as a substitute for transfusion. It should not be used when immediate correction of anemia is required, nor as a replacement for transfusion in patients who need urgent hemoglobin correction. Additionally, Vafseo is not indicated for patients with chronic kidney disease who are not receiving dialysis.

Provider Actions and Prior Authorization Process

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial approvals are issued for 12 months when BOTH diagnosis and patient factors below are met.

Diagnosis: anemia due to chronic kidney disease (CKD)
Patient has been receiving dialysis for at least three months
Authorization length: 12 months

Documentation Required

Reauthorization and Clinical Documentation

Reauthorization will be approved for 12 months when there is documentation of a positive clinical response to Vafseo therapy. State mandates, federal regulatory requirements, and the member's benefit plan may also affect coverage decisions.

Documentation of positive clinical response required for reauthorization
Authorization length: 12 months

Note

Use of Automated Approval

UnitedHealthcare may use previous claims or medication history, diagnosis codes (ICD-10), and claim logic to approve initial authorizations or reauthorizations without additional documentation. Automated approval or re-approval processes vary by program and therapeutic class.

Automated approval may rely on prior claims/medication history and ICD-10 diagnosis codes
Use of automated processes varies by program and therapeutic class

Denial Risk

Initial Authorization Requirements

Initial authorization requests that lack the required diagnosis of CKD-related anemia and documentation that the patient has received dialysis for at least three months will not meet criteria.

Requests missing both diagnosis and dialysis documentation will be denied or returned for more information

Definitions

Vafseo (vadadustat) — definition, indication, and key limitations

Drug classHypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor

Brand and generic nameVafseo (vadadustat)

Indication (covered)Treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Limitations of use — quality of lifeHas not been shown to improve quality of life, fatigue, or patient well-being.

Limitations of use — transfusion substituteNot indicated as a substitute for transfusion in patients requiring immediate correction of anemia or for patients with CKD not on dialysis.

Background

Vafseo (vadadustat) is a hypoxia‑inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months. Its mechanism is modulation of the hypoxia‑inducible factor pathway via prolyl hydroxylase inhibition to stimulate erythropoiesis. Note that Vafseo has specific limitations of use, including lack of demonstrated benefit for quality of life or fatigue and that it is not a substitute for transfusion.